



## OvaScience Presents Potential New Approach to Addressing Infertility at New York Society of Reproductive Medicine Meeting

February 27, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2013-- [OvaScience<sup>SM</sup>](#) (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that Co-Founder Jonathan L. Tilly, Ph.D., and Chief Executive Officer and Co-Founder Michelle Dipp, M.D., Ph.D., will be featured speakers at the New York Society of Reproductive Medicine (NYSRM) 2013 First Educational Meeting, being held Wednesday, February 27, 2013 in New York City.

Drs. Tilly and Dipp will give a joint presentation on a potential new approach to treating infertility, which is based on Dr. Tilly's discovery of egg precursor cells (EggPC<sup>SM</sup>) and is the foundation of OvaScience's EggPC technology platform. Dr. Tilly's lecture, titled " *Bioenergetics and Egg Quality: Development of AUGMENT to Improve IVF Outcome*" will address the science that led to the conceptual development of AUGMENT<sup>SM</sup> as a method for improving egg quality. Dr. Dipp will follow with an overview of the clinical development of AUGMENT, the Company's first product candidate that aims to improve egg quality and thereby increase the success of in vitro fertilization (IVF).

"It is a wonderful opportunity to participate in the NYSRM lecture series and share the work we are doing to advance the discovery of egg precursor cells for the potential benefit of women struggling with infertility," said Dr. Tilly, a Massachusetts General Hospital-based Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and Affiliated Faculty Member of the Harvard Stem Cell Institute in Boston.

### About OvaScience

OvaScience (OTC: OVSC) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company's patented technology is based on the discovery of egg precursor cells (EggPC<sup>SM</sup>), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT<sup>SM</sup> aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience's team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit [www.ovascience.com](http://www.ovascience.com).

### Forward-Looking Statements

*This press release includes forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "aim," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.*

Source: OvaScience, Inc.

OvaScience, Inc.  
Theresa McNeely, 617-299-7356  
Head of Corporate Communications  
[tmcneely@ovascience.com](mailto:tmcneely@ovascience.com)

